BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35729312)

  • 1. Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2.
    Aljarf R; Shen M; Pires DEV; Ascher DB
    Sci Rep; 2022 Jun; 12(1):10458. PubMed ID: 35729312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
    Hart SN; Hoskin T; Shimelis H; Moore RM; Feng B; Thomas A; Lindor NM; Polley EC; Goldgar DE; Iversen E; Monteiro ANA; Suman VJ; Couch FJ
    Genet Med; 2019 Jan; 21(1):71-80. PubMed ID: 29884841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
    Toland AE; Andreassen PR
    J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics.
    Ernst C; Hahnen E; Engel C; Nothnagel M; Weber J; Schmutzler RK; Hauke J
    BMC Med Genomics; 2018 Mar; 11(1):35. PubMed ID: 29580235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1- and BRCA2-specific in silico tools for variant interpretation in the CAGI 5 ENIGMA challenge.
    Padilla N; Moles-Fernández A; Riera C; Montalban G; Özkan S; Ootes L; Bonache S; Díez O; Gutiérrez-Enríquez S; de la Cruz X
    Hum Mutat; 2019 Sep; 40(9):1593-1611. PubMed ID: 31112341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer.
    Trujillano D; Weiss ME; Schneider J; Köster J; Papachristos EB; Saviouk V; Zakharkina T; Nahavandi N; Kovacevic L; Rolfs A
    J Mol Diagn; 2015 Mar; 17(2):162-70. PubMed ID: 25556971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots".
    Dines JN; Shirts BH; Slavin TP; Walsh T; King MC; Fowler DM; Pritchard CC
    Genet Med; 2020 May; 22(5):825-830. PubMed ID: 31911673
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Khandakji M; Habish HHA; Abdulla NBS; Kusasi SAA; Abdou NMG; Al-Mulla HMMA; Al Sulaiman RJAA; Bu Jassoum SM; Mifsud B
    Physiol Genomics; 2023 Aug; 55(8):315-323. PubMed ID: 37335020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
    Meyer P; Voigtlaender T; Bartram CR; Klaes R
    Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
    Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico analysis of BRCA1 and BRCA2 missense variants and the relevance in molecular genetic testing.
    Poon KS
    Sci Rep; 2021 May; 11(1):11114. PubMed ID: 34045478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of common BRCA1 and BRCA2 variants.
    Deffenbaugh AM; Frank TS; Hoffman M; Cannon-Albright L; Neuhausen SL
    Genet Test; 2002; 6(2):119-21. PubMed ID: 12215251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
    Kim HK; Lee EJ; Lee YJ; Kim J; Kim Y; Kim K; Lee SW; Chang S; Lee YJ; Lee JW; Lee W; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
    J Hum Genet; 2020 Mar; 65(3):209-220. PubMed ID: 31907386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
    Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN
    Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants.
    Cline MS; Babbi G; Bonache S; Cao Y; Casadio R; de la Cruz X; Díez O; Gutiérrez-Enríquez S; Katsonis P; Lai C; Lichtarge O; Martelli PL; Mishne G; Moles-Fernández A; Montalban G; Mooney SD; O'Conner R; Ootes L; Özkan S; Padilla N; Pagel KA; Pejaver V; Radivojac P; Riera C; Savojardo C; Shen Y; Sun Y; Topper S; Parsons MT; Spurdle AB; Goldgar DE;
    Hum Mutat; 2019 Sep; 40(9):1546-1556. PubMed ID: 31294896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.